Table 2.
Prevalence of NKG2D Thr72Ala Polymorphisms Among Patients with Cervical Cancer and Healthy Individuals
| Genotype distribution (frequency) | Minor allele frequency | Odds Ratio (95% CI) | p | ptrend | |||
|---|---|---|---|---|---|---|---|
| n | Ala/Ala | Ala/Thr | Thr/Thr | ||||
| Controls n=366 | 232 (0.63) | 112 (0.31) | 22 (0.06) | 0.21 | |||
| Cervical cancer in stage I, II, III and IV n=353 | 246 (0.70) | 96 (0.27) | 11 (0.03) | 0.17 | 0.5029 (0.2401–1.053)a | 0.0637d | 0.0313 |
| 0.7531 (0.5517–1.028)b | 0.0736d | ||||||
| 0.7410 (0.5683–0.9662)c | 0.0265d | ||||||
| Cervical cancer in stage III and IV n=155 | 123 (0.79) | 29 (0.19) | (0.02) | 0.11 | 0.3086 (0.09097–1.047)a | 0.0461e | 0.0003 |
| 0.4504 (0.2891–0.7018)b | 0.0003d | ||||||
| 0.4699 (0.3170–0.6967) c | 0.0001d | ||||||
The Odds Ratio (OR) was calculated for patients a(Thr/Thr genotype vs Ala/Thr and Ala/Ala enotypes).
b
(Thr/Thr and Ala/Thr genotype vs Ala/Ala genotype). We also determined the OR for the risk allele.
c
(Thr vs Ala allele).
d
uncorrected Chi2.
e
Fisher exact test.
CI, confidence interval.